Prime Medicine, Inc. (PRME)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
3.61 USD
-0.03
(-0.824%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.59 -0.02 (-0.020%) ⇩ (Aug. 28, 2026, 7:36 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:32 a.m. EDT
Prime Medicine presents a classic value trap scenario where the market has priced out the biotech risk entirely. Fundamentally, the company is in distress with negative earnings, negative free cash flow, and a crushing 72% decline over the last two years. While the pipeline includes promising gene-editing technologies for Wilson's disease and liver conditions, the balance sheet is fragile with debt exceeding cash reserves, and the operating margins are deeply negative. The lack of a dividend and the severe multi-year price trajectory confirm that the market views the current business execution as insufficient to sustain the current valuation. Although analysts maintain a 'Buy' rating with a target price nearly double the current level, this appears to be a speculative bet on a binary clinical success event rather than a sound investment in the current operational reality. The options market agrees with the pessimism, with traders loading up on cheap puts to protect against further deterioration, signaling that the consensus view is for continued volatility and downside risk until the next major data readout. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.091598 |
| AutoARIMA | 0.092272 |
| AutoETS | 0.092272 |
| AutoTheta | 0.092297 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.019 |
| Excess Kurtosis | 0.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 282.544 |
| Revenue per Share | 0.024 |
| Market Cap | 654,770,432 |
| Forward P/E | -4.06 |
| Beta | 2.31 |
| Website | https://primemedicine.com |
As of Aug. 22, 2026, 3:32 a.m. EDT: Speculators are positioning heavily for downside protection rather than upside speculation. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts showing massive accumulation (e.g., 1.4k contracts at the $12 strike for Jan 2028). This distribution suggests a 'bear put spread' strategy or hedging against a potential clinical trial failure or regulatory setback, rather than a bet on the stock reaching analyst targets.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15705132 |
| Address1 | 60 First Street |
| All Time High | 21.73 |
| All Time Low | 1.11 |
| Ask | 3.71 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 2,902,190 |
| Average Daily Volume3 Month | 3,313,652 |
| Average Volume | 3,313,652 |
| Average Volume10Days | 2,902,190 |
| Beta | 2.312 |
| Bid | 2.24 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.225 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.61 |
| Current Ratio | 3.055 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.7 |
| Day Low | 3.485 |
| Debt To Equity | 282.544 |
| Display Name | Prime Medicine |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,968,200 |
| Earnings Timestamp Start | 1,793,968,200 |
| Ebitda | -189,122,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.488 |
| Enterprise To Revenue | 161.955 |
| Enterprise Value | 659,641,536 |
| Eps Current Year | -0.9426 |
| Eps Forward | -0.88992 |
| Eps Trailing Twelve Months | -1.04 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3475 |
| Fifty Day Average Change | 0.2624998 |
| Fifty Day Average Change Percent | 0.07841667 |
| Fifty Two Week Change Percent | 15.7051325 |
| Fifty Two Week High | 6.94 |
| Fifty Two Week High Change | -3.3300002 |
| Fifty Two Week High Change Percent | -0.4798271 |
| Fifty Two Week Low | 2.67 |
| Fifty Two Week Low Change | 0.9399998 |
| Fifty Two Week Low Change Percent | 0.35205984 |
| Fifty Two Week Range | 2.67 - 6.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,666,272,600,000 |
| Float Shares | 112,250,503 |
| Forward Eps | -0.88992 |
| Forward P E | -4.0565443 |
| Free Cashflow | -75,780,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 146 |
| Fullday Change | -0.0300002 |
| Fullday Change Percent | -0.824182 |
| Fullday Price | 3.59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -142,128,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23663001 |
| Held Percent Institutions | 0.71147 |
| Implied Shares Outstanding | 181,376,856 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-10-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Prime Medicine, Inc. |
| Market | us_market |
| Market Cap | 654,770,432 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1673776358 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -187,892,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 662,025,524 |
| Number Of Analyst Opinions | 11 |
| Open | 3.57 |
| Operating Cashflow | -156,051,008 |
| Operating Margins | -37.50867 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 465 0013 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -0.5540161 |
| Post Market Price | 3.59 |
| Post Market Time | 1,787,960,186 |
| Previous Close | 3.64 |
| Price Eps Current Year | -3.8298323 |
| Price Hint | 4 |
| Price To Book | 16.044445 |
| Price To Sales Trailing12 Months | 160.75876 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.0 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.0300002 |
| Regular Market Change Percent | -0.824182 |
| Regular Market Day High | 3.7 |
| Regular Market Day Low | 3.485 |
| Regular Market Day Range | 3.485 - 3.7 |
| Regular Market Open | 3.57 |
| Regular Market Previous Close | 3.64 |
| Regular Market Price | 3.61 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,693,505 |
| Return On Assets | -0.4652 |
| Return On Equity | -3.7328699 |
| Revenue Growth | 0.035 |
| Revenue Per Share | 0.024 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 181,376,856 |
| Shares Percent Shares Out | 0.19309999 |
| Shares Short | 35,022,290 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 33,536,516 |
| Short Name | Prime Medicine, Inc. |
| Short Percent Of Float | 0.2468 |
| Short Ratio | 13.0 |
| Source Interval | 15 |
| State | MA |
| Symbol | PRME |
| Target High Price | 11.0 |
| Target Low Price | 4.25 |
| Target Mean Price | 7.11364 |
| Target Median Price | 7.0 |
| Total Cash | 95,071,000 |
| Total Cash Per Share | 0.534 |
| Total Debt | 112,478,000 |
| Total Revenue | 4,073,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.54405 |
| Two Hundred Day Average Change | 0.06594992 |
| Two Hundred Day Average Change Percent | 0.01860863 |
| Type Disp | Equity |
| Volume | 2,693,505 |
| Website | https://primemedicine.com |
| Zip | 2,141 |